logo
Plus   Neg
Share
Email

American Axle Projects FY20 Sales Below Estimates - Quick Facts

While reporting financial results for the fourth quarter on Friday, American Axle & Manufacturing Holdings, Inc. or AAM (AXL) initiated its sales guidance for the full-year 2020. It also provided 2020-2022 new business backlog.

For fiscal 2020, the company now projects sales in the range of $5.8 billion to $6.0 billion, which includes lower metal market passthroughs to customers at current market rates. North American light vehicle production is expected in a range of 16.3 million to 16.5 million units.

On average, analysts polled by Thomson Reuters expect the company to report sales of $6.09 billion for the year.

"In 2020, we are focused on further free cash flow generation and debt reduction while continuing to invest in advanced propulsion technologies to drive future profitable growth for AAM," said David Dauch, AAM's Chairman and CEO.

Providing 2020-2022 new business backlog details, AAM said its gross new and incremental business backlog launching from 2020 - 2022 is estimated at approximately $750 million in future annual sales.

AAM expects the launch cadence of the three-year backlog to be approximately $400 million in 2020, $200 million in 2021 and $150 million in 2022. AAM's updated backlog estimate contemplates the sale of the U.S. iron casting operations completed in December 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pizza Hut's large Original Pan Pizza is now available at locations across the U.S. for $10.99. The fast food chain, a subsidiary of Yum! Brands Inc., said that fans can now get a large Original Pan Pizza with up to three of their favorite toppings, without needing to stretch their wallets. The Original Pan Pizza is a buttery golden-brown color. The U.S. Food and Drug Administration approved the first drug to treat adults and children aged 12 years and older with hypereosinophilic syndrome for six months or longer without another identifiable non-blood related cause of the disease. GlaxoSmithKline's Nucala (mepolizumab) is the first FDA-approved drug in nearly 14 years to treat this group of rare and debilitating blood diseases. Uber has won a legal battle to continue to operate in London, one of its largest markets. The ride-hailing company has been granted an 18-month license to operate in London after overturning the ban on an appeal for the second time. The Westminister Magistrates Court found Uber London Ltd. a "fit and proper" company to run the services in London.
Follow RTT